Introduction {#S1}
============

Multidrug-resistant (MDR) pathogens, especially the ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species), are the leading cause of nosocomial infections throughout the world, which is usually caused by excessive drug usage or prescription and inappropriate use of antimicrobials. Understanding the mechanisms, developing novel antimicrobial agents, and knowing the latest antimicrobial resistance patterns of bacterial pathogens are crucial to combat these public health challenges ([@B12]; [@B13]; [@B3]).

Cefoselis is a member of the fourth-generation cephalosporins which exhibit a wider antibacterial spectrum activity than the third-generation cephalosporins to both Gram-negative and Gram-positive bacteria ([@B6]). The wide antibacterial spectrum of cefoselis is attributed to the resistance to hydrolysis by the chromosomal β-lactamases and the rapid penetration through the bacterial cell wall ([@B4]). However, few reports have been published in China on the antimicrobial activity of cefoselis against common bacterial pathogens. The objective of this study was to better understand the *in vitro* activity of cefoselis against common Gram-positive and Gram-negative bacterial pathogens in China.

Materials and Methods {#S2}
=====================

Ethics {#S2.SS1}
------

The protocol was approved by the Human Research Ethics Committee of Peking Union Medical College Hospital (no. S-K262). Peking Union Medical College Hospital did not require written informed consent from participants because this was an *in vitro* study on bacteria isolates without any private data of the human participants.

Clinical Isolates {#S2.SS2}
-----------------

A total of 1188 bacterial isolates derived from 18 hospitals in China (January 2014--December 2016) were studied. The bacterial species distribution is shown in [Table 1](#T1){ref-type="table"}. The isolates from each of the participating hospitals were re-identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (Bruker Daltonics GmbH, Bremen, Germany) at the Central Lab, Peking Union Medical College Hospital (Beijing), China.

###### 

Distribution of bacterial species.

  **Organisms**                   **Number**   **Percentage**
  ------------------------------- ------------ ----------------
  *E. coli* (ESBL+)               134          11.3
  *E. coli* (ESBL−)               107          9.0
  *K. pneumoniae* (ESBL+)         118          9.9
  *K. pneumoniae* (ESBL−)         106          8.9
  *P. mirabilis* (ESBL+)          33           2.8
  *P. mirabilis* (ESBL−)          33           2.8
  *C. freundii*                   30           2.5
  *E. aerogenes*                  30           2.5
  *E. cloacae*                    30           2.5
  *S. marcescens*                 30           2.5
  *P. vulgaris*                   30           2.5
  *A. baumannii*                  198          16.7
  *P. aeruginosa*                 30           2.5
  MRSA                            97           8.2
  MSSA                            100          8.4
  PSSP                            25           2.1
  PRSP                            15           1.3
  Beta-hemolytic *streptococci*   27           2.3
  Viridans group *streptococci*   15           1.3
  Total                           1,188        100.0

ESBL, extended-spectrum β-lactamase; MRSA, methicillin-resistant

S. aureus

; MSSA, methicillin-sensitive

S. aureus

; PSSP, penicillin-susceptible

S. pneumoniae

; PRSP, penicillin-resistant

S. pneumoniae

.

Antimicrobial Susceptibility Test Method {#S2.SS3}
----------------------------------------

Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method following Clinical and Laboratory Standards Institute (CLSI) guidelines. Thirty-two antimicrobial agents were tested against the isolates, among which 17 agents were against Gram-negative organisms, 24 agents against *Staphylococcus* spp., and 19 agents against *Streptococcus* spp. Cefoselis was obtained from Hansoh Pharma, and the other agents were provided by AstraZeneca. Interpretation of the antimicrobial testing results was based on CLSI M100-S28 ([@B1]). *Escherichia coli* ATCC 25922, *P. aeruginosa* ATCC 27853, *K. pneumoniae* ATCC 700603, *S. aureus* ATCC 29213, and *Streptococcus pneumoniae* ATCC 49619 were used as the quality control strains.

Extended-Spectrum β-Lactamase Detection {#S2.SS4}
---------------------------------------

Phenotypic identification of extended-spectrum β-lactamase (ESBL) production in *E. coli*, *K. pneumoniae*, and *Proteus mirabilis*, was carried out using CLSI-recommended methods. If the cefotaxime or ceftazidime MICs were ≥ 2 μg/ml, the MICs of cefotaxime + clavulanic acid (4 μg/ml) or ceftazidime + clavulanic acid (4 μg/ml) were comparatively determined. ESBL production was defined as an eightfold or greater decrease in MICs for cefotaxime or ceftazidime tested in combination with clavulanic acid compared to their MICs without clavulanic acid.

Results {#S3}
=======

*In vitro* Activity of Antimicrobial Agents Against Enterobacteriaceae {#S3.SS1}
----------------------------------------------------------------------

Against ESBL-producing *E. coli*, *K. pneumoniae*, and *P. mirabilis* isolates, cefoselis, cefepime, cefotaxime, and ceftriaxone showed relatively low susceptibility rates, with drug resistance rates of \> 87%. Against non-ESBL-producing strains, most antibiotics revealed good activity, of which cefoselis, cefepime, showed \> 94% antimicrobial susceptibility rates. For *Citrobacter freundii*, *Enterobacter aerogenes*, *Enterobacter cloacae*, *Serratia marcescens*, and *Proteus vulgaris* isolates, the susceptibility rates for cefoselis ranged from 56.7% to 83.3%, which were slightly lower than that of cefepime, with susceptibility rates ranging from 70% to 100%. Meropenem and amikacin exhibited high activity against all the Enterobacteriaceae strains ([Tables 2](#T2){ref-type="table"},[3](#T3){ref-type="table"}).

###### 

*In vitro* activity of antimicrobial agents against ESBL-positive and ESBL-negative *Escherichia coli*, *Klebsiella pneumoniae* and *Proteus mirabilis* strains.

  **Antimicrobial**         ***E. coli***   ***E. coli***   ***K. pneumoniae***   ***K. pneumoniae***   ***P. mirabilis***   ***P. mirabilis***                                         
  ------------------------- --------------- --------------- --------------------- --------------------- -------------------- -------------------- ------ ------- ------- ------- ------ -------
  Piperacillin/tazobactam   12.7            84.3            1.9                   97.2                  23.7                 65.3                 2.8    97.2    3.0     93.9    3.0    93.9
  Ceftazidime               55.2            30.6            0                     100.0                 59.3                 30.5                 1.9    97.2    9.1     90.9    0      100.0
  Ceftriaxone               99.3            0.7             0                     99.1                  94.9                 4.2                  2.8    94.3    100.0   0.0     0      100.0
  Cefotaxime                99.3            0.7             0                     100.0                 94.9                 5.1                  3.8    95.3    97.0    0.0     0      100.0
  Cefoselis                 97.8            2.2             0                     100.0                 93.2                 6.8                  0.9    94.3    97.0    3.0     3.0    97.0
  Cefepime                  91.0            3.7             0                     100.0                 90.7                 6.8                  0      100.0   87.9    3.0     0      97.0
  Cefoxitin                 20.9            58.2            1.9                   93.5                  18.6                 78.0                 12.3   84.0    3.0     93.9    0      100.0
  Aztreonam                 83.6            8.2             0                     100.0                 81.4                 14.4                 0.9    99.1    41.4    58.6    21.2   78.8
  Ertapenem                 0               92.5            0                     100.0                 0                    92.4                 0      100.0   0       97.0    0      100.0
  Imipenem                  0               97.8            0                     100.0                 0                    94.9                 0      96.2    15.2    27.3    9.1    45.5
  Meropenem                 0               100.0           0                     100.0                 0                    100.0                0      100.0   0       100.0   0      100.0
  Amikacin                  3.0             95.5            0                     100.0                 7.6                  91.5                 0.9    99.1    6.1     90.9    0      100.0
  Ciprofloxacin             78.4            20.1            29.0                  69.2                  55.9                 40.7                 11.3   87.7    90.9    9.1     48.5   48.5
  Levofloxacin              72.4            20.9            27.1                  71.0                  46.6                 47.5                 10.4   87.7    69.7    27.3    27.3   63.6
  Minocycline               47.0            40.3            28.0                  54.2                  44.1                 38.1                 21.7   69.8    --      --      --     --
  Tetracycline              87.3            12.7            84.1                  15.0                  66.1                 32.2                 25.5   67.9    --      --      --     --
  Tigecycline               0.7             92.5            0                     98.1                  3.4                  82.2                 0.9    90.6    --      --      --     --

ESBL, extended-spectrum β-lactamase; R, resistant; S, sensitive.

###### 

*In vitro* activity of antimicrobial agents against Enterobacteriaceae strains.

  **Antimicrobial agents**   ***C. freundii* (30)**   ***E. aerogenes* (30)**   ***E. cloacae* (30)**   ***S. marcescens* (30)**   ***P. vulgaris* (30)**                                
  -------------------------- ------------------------ ------------------------- ----------------------- -------------------------- ------------------------ ------- ------ ------ ------ -------
  Piperacillin/tazobactam    20.0                     73.3                      20.0                    63.3                       26.7                     60.0    13.3   83.3   0      93.3
  Ceftazidime                30.0                     63.3                      33.3                    60.0                       43.3                     46.7    3.3    93.3   0      100.0
  Ceftriaxone                50.0                     43.3                      40.0                    53.3                       60.0                     36.7    23.3   73.3   53.3   3.3
  Cefotaxime                 50.0                     43.3                      50.0                    43.3                       60.0                     33.3    30.0   60.0   46.7   16.7
  Cefoselis                  30.0                     56.7                      10.0                    83.3                       33.3                     56.7    20.0   80.0   3.3    83.3
  Cefepime                   26.7                     70.0                      10.0                    90.0                       13.3                     70.0    16.7   80.0   0      100.0
  Cefoxitin                  63.3                     23.3                      90.0                    3.3                        93.3                     3.3     80.0   0.0    13.3   73.3
  Aztreonam                  43.3                     56.7                      36.7                    63.3                       56.7                     43.3    13.3   86.7   0      96.7
  Ertapenem                  6.7                      90.0                      10.0                    90.0                       16.7                     60.0    13.3   86.7   6.7    93.4
  Imipenem                   6.7                      86.7                      6.7                     50.0                       6.7                      83.3    16.7   56.7   66.7   6.7
  Meropenem                  6.7                      93.3                      3.3                     96.7                       6.7                      93.3    13.3   83.3   3.3    96.7
  Amikacin                   3.3                      90.0                      0                       100.0                      0                        100.0   3.3    93.3   3.3    96.7
  Ciprofloxacin              26.7                     70.0                      10.0                    83.3                       40.0                     53.3    23.3   73.3   30.0   66.7
  Levofloxacin               26.7                     66.7                      6.7                     90.0                       30.0                     60.0    13.3   73.3   6.7    80.0
  Minocycline                16.7                     70.0                      10.0                    66.7                       30.0                     63.3    6.7    86.7   --     --
  Tetracycline               36.7                     60.0                      43.3                    56.7                       36.7                     63.3    60.0   10.0   --     --
  Tigecycline                0                        100.0                     0                       96.7                       0                        93.3    0      93.3   --     --

R, resistant; S, sensitive.

*In vitro* Activity of Antimicrobial Agents Against Non-fermentative Gram-Negative Organisms {#S3.SS2}
--------------------------------------------------------------------------------------------

The most active agents against *A. baumannii* were tigecycline and minocycline, with susceptibility rates of 58.6% and 45.5%, respectively. The other analyzed agents were less effective, with susceptibility rates of \< 30%. Furthermore, against *P. aeruginosa* isolates, amikacin exhibited the highest *in vitro* activity, with a susceptibility rate of 93.3%. The susceptibility rates for cefoselis, cefepime, and ceftazidime were all 73.3% each for this organism ([Table 4](#T4){ref-type="table"}).

###### 

*In vitro* activity of antimicrobial agents against *Acinetobacter baumannii* and *Pseudomonas aeruginosa* strains.

  **Antimicrobial agents**   ***A. baumannii* (198)**   ***P. aeruginosa* (30)**           
  -------------------------- -------------------------- -------------------------- ------- ------
  Piperacillin/tazobactam    75.3                       23.2                       13.3    80.0
  Ceftazidime                76.8                       20.7                       20.0    73.3
  Ceftriaxone                78.8                       7.1                        96.7    0
  Cefotaxime                 78.8                       14.6                       100.0   0
  Cefoselis                  80.8                       18.7                       26.7    73.3
  Cefepime                   75.8                       19.7                       20.0    73.3
  Cefoxitin                  96.5                       2.5                        96.7    0
  Aztreonam                  84.3                       5.1                        20      73.3
  Ertapenem                  --                         --                         --      --
  Imipenem                   75.3                       24.7                       20.0    80.0
  Meropenem                  75.3                       24.2                       10.0    76.7
  Amikacin                   69.7                       29.8                       6.7     93.3
  Ciprofloxacin              76.8                       21.2                       16.7    76.7
  Levofloxacin               59.6                       23.2                       16.7    76.7
  Minocycline                28.3                       45.5                       --      --
  Tetracycline               81.3                       16.2                       --      --
  Tigecycline                22.7                       58.6                       96.7    3.3

R, resistant; S, sensitive.

*In vitro* Activity of Antimicrobial Agents Against MRSA and MSSA {#S3.SS3}
-----------------------------------------------------------------

Against methicillin-resistant *S. aureus* (MRSA) strains, linezolid, vancomycin, and teicoplanin exhibited a susceptibility rate of 100% each, followed by tigecycline (97.9%), and trimethoprim--sulfamethoxazole (TMP-SMX) (94.8%). All strains were resistant to ceftazidime, ceftriaxone, cefoselis, and cefepime. Against 100 methicillin-sensitive *S. aureus* (MSSA) strains, most antibiotics showed good activity, except for ampicillin, tetracycline, and erythromycin. All strains were susceptible to ceftazidime, ceftriaxone, cefoselis, and cefepime ([Table 5](#T5){ref-type="table"}).

###### 

*In vitro* activity of antimicrobial agents against MRSA and MSSA strains.

  **Antimicrobial agents**         **MRSA (97)**   **MSSA (100)**          
  -------------------------------- --------------- ---------------- ------ -------
  Ampicillin                       100.0           0                90.0   10
  Oxacillin                        100.0           0                0      100.0
  Amoxicillin/clavulanate          100.0           0                0      100.0
  Piperacillin/tazobactam          100.0           0                0      100.0
  Ceftaroline                      4.1             35.1             0      95.0
  Ceftazidime                      100.0           0                0      100.0
  Ceftriaxone                      100.0           0                0      100.0
  Cefoselis                        100.0           0                0      100.0
  Cefepime                         100.0           0                0      100.0
  Doripenem                        100.0           0                0      100.0
  Meropenem                        100.0           0                0      100.0
  Gentamicin                       49.5            38.1             18.0   81.0
  Levofloxacin                     79.4            20.6             23.0   75.0
  Moxifloxacin                     77.3            19.6             15.0   77.0
  Trimethoprim--sulfamethoxazole   5.2             94.8             2.0    98.0
  Clindamycin                      47.4            50.5             21.0   78.0
  Daptomycin                       0               99               0      99.0
  Erythromycin                     82.5            8.2              38.0   60.0
  Linezolid                        0               100.0            0      100.0
  Vancomycin                       0               100.0            0      100.0
  Teicoplanin                      0               100.0            0      100.0
  Minocycline                      0               88.7             0      100.0
  Tetracycline                     60.8            36.1             43.0   52.0
  Tigecycline                      2.1             97.9             0      100.0

MRSA, methicillin-resistant

S. aureus

; MSSA, methicillin-sensitive

S. aureus

; R, resistant; S, sensitive.

*In vitro* Activity of Antimicrobial Agents Against *Streptococcus* Strains {#S3.SS4}
---------------------------------------------------------------------------

For the penicillin-susceptible *S. pneumoniae* (PSSP), beta-hemolytic *Streptococcus* strains, and viridans group *Streptococcus* strains, cefoselis and cefepime both showed very high antimicrobial activities, with susceptibility rates of \> 90%. Against 15 penicillin-resistant *S. pneumoniae* (PRSP) strains, the susceptibility rate of cefoselis was higher than that of cefepime (60.0% *vs*. 40.0%). Linezolid, vancomycin, and tigecycline exhibited 100% antimicrobial activity against all the *Streptococcus* strains ([Table 6](#T6){ref-type="table"}).

###### 

*In vitro* activity of antimicrobial agents against *Streptococcus* strains.

  **Antimicrobial agents**   **PSSP (25)**   **PRSP (15)**   **Beta-hemolytic**   **Viridans group**                         
  -------------------------- --------------- --------------- -------------------- -------------------- ------ ------- ------ -------
  Penicillin                 0               100.0           100.0                0                    0      100.0   0      100.0
  Amoxicillin/clavulanate    0               100.0           40.0                 40.0                 --     --      --     --
  Ceftaroline                0               100.0           0                    100.0                0      92.6    0      100.0
  Ceftazidime                4.0             92.0            86.7                 0                    7.4    92.6    13.3   86.7
  Ceftriaxone                0               96.0            40.0                 53.3                 0      92.6    6.7    91.7
  Cefoselis                  4.0             96.0            0                    60.0                 7.4    92.6    0      100.0
  Cefepime                   4.0             96.0            20.0                 40.0                 7.4    92.6    6.7    93.3
  Doripenem                  0               100.0           0                    100.0                0      92.6    0      100.0
  Meropenem                  4.0             92.0            40.0                 6.7                  0      92.6    0      100.0
  Levofloxacin               4.0             96.0            0                    100.0                46.2   53.8    6.7    80.0
  Moxifloxacin               32.0            68.0            0                    100.0                --     --      --     --
  Clindamycin                100.0           0               100.0                0                    74.1   22.2    66.7   33.3
  Daptomycin                 --              --              --                   --                   --     92.7    --     93.3
  Erythromycin               76.0            24.0            100.0                0                    48.1   51.9    80.0   13.3
  Linezolid                  0               100.0           0                    100.0                0      100.0   0      100.0
  Vancomycin                 0               100.0           0                    100.0                0      100.0   0      100.0
  Minocycline                12.0            48.0            6.7                  73.3                 33.3   48.1    6.7    80.0
  Tetracycline               88.0            8.0             93.3                 6.7                  74.1   22.2    66.7   33.3
  Tigecycline                0               100.0           0                    100.0                0      100.0   0      100.0

PSSP, penicillin-susceptible

S. pneumoniae

; PRSP, penicillin-resistant

S. pneumoniae

; R, resistant; S, sensitive.

Comparison of Cefoselis and Cefepime Against Common Clinical Pathogens {#S3.SS5}
----------------------------------------------------------------------

Cefoselis exhibited a slightly lower antimicrobial activity than cefepime against Enterobacteriaceae and non-fermentative Gram-negative organisms, but a little higher activity than cefepime against MRSA, MSSA, PSSP, beta-hemolytic *Streptococcus*, and viridans group *Streptococcus* strains. The cumulative percentage MIC distributions of cefoselis and cefepime against common clinical pathogens are shown in [Table 7](#T7){ref-type="table"}.

###### 

Cumulative percentage MIC distributions of cefoselis and cefepime against common clinical pathogens collected in China.

  **Species (*n*) and drug**           **Cumulative% isolates at or below various MICs (μg/ml)^a^**                                                                                                                                                            
  ------------------------------------ -------------------------------------------------------------- ------ ------ ------ ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------
  *E. coli* (ESBL+) (134)              Cefoselis                                                                    1.5    2.2        2.2        2.2        2.2        2.2        2.2        2.2        3.7        8.2        11.9       20.1       20.9       **100**
                                       Cefepime                                                                     0.7    1.5        2.2        2.2        2.2        3.7        5.2        9.0        18.7       26.9       32.8       36.6       40.3       **100**
  *E. coli* (ESBL-) (107)              Cefoselis                                                      1.9    17.8   71.0   **92.5**   98.1       98.1       98.1       100                                                                                     
                                       Cefepime                                                       0.9    16.8   66.4   **94.4**   97.2       100                                                                                                           
  *K. pneumoniae* (ESBL+) (118)        Cefoselis                                                             0.8    4.2    5.1        5.9        5.9        6.8        6.8        6.8        6.8        6.8        6.8        12.7       16.1       16.9       **100**
                                       Cefepime                                                              0.8    4.2    5.1        5.1        5.1        6.8        6.8        6.8        9.3        11.9       17.8       21.2       26.3       31.4       **100**
  *K. pneumoniae* (ESBL-) (106)        Cefoselis                                                      1.9    30.2   60.4   81.1       **91.5**   93.4       93.4       94.3       97.2       99.1       99.1       100                                         
                                       Cefepime                                                       3.8    46.2   67.9   82.1       **91.5**   92.5       96.2       100                                                                                     
  *P. mirabilis* (ESBL+) (33)          Cefoselis                                                                                                            3.0        3.0        3.0        3.0        3.0        6.1        9.1        9.1        9.1        **100**
                                       Cefepime                                                                                       3.0        3.0        3.0        3.0        3.0        12.1       12.1       21.2       30.3       30.3       30.3       **100**
  *P. mirabilis* (ESBL-) (33)          Cefoselis                                                      3.0    39.4   48.5   60.6       66.7       75.8       81.8       **97.0**   97.0       97.0       100                                                    
                                       Cefepime                                                              42.4   45.5   51.5       57.6       69.7       87.9       **97.0**   97.0       100                                                               
  *C. freundii* (30)                   Cefoselis                                                      26.7   43.3   46.7   50.0       53.3       53.3       56.7       56.7       60.0       70.0       70.0       73.3       80.0       83.3       83.3       **100**
                                       Cefepime                                                       30.0   46.7   53.3   56.7       60.0       63.3       63.3       70.0       73.3       73.3       83.3       83.3       83.3       **90.0**   93.3       100
  *E. aerogenes* (30)                  Cefoselis                                                      10.0   33.3   43.3   50.0       63.3       70.0       73.3       83.3       **90.0**   90.0       90.0       90.0       90.0       90.0       93.3       100
                                       Cefepime                                                       6.7    43.3   46.7   63.3       76.7       86.7       **90.0**   90.0       90.0       90.0       93.3       96.7       96.7       96.7       96.7       100
  *E. cloacae* (30)                    Cefoselis                                                      3.3    30.0   36.7   36.7       43.3       46.7       46.7       56.7       60.0       66.7       66.7       83.3       86.7       **93.3**   93.3       100
                                       Cefepime                                                       10.0   30.0   33.3   43.3       50.0       56.7       63.3       70.0       76.7       86.7       **93.3**   96.7       96.7       96.7       100        
  *S. marcescens* (30)                 Cefoselis                                                      30.0   70.0   73.3   76.7       76.7       76.7       76.7       80.0       80.0       80.0       80.0       80.0       80.0       80.0       80.0       **100**
                                       Cefepime                                                       10.0   66.7   73.3   76.7       76.7       76.7       76.7       80.0       80.0       83.3       86.7       86.7       86.7       86.7       86.7       **100**
  *P. vulgaris* (30)                   Cefoselis                                                             3.3    30.0   46.7       60.0       70.0       76.7       83.3       **93.3**   96.7       96.7       96.7       96.7       96.7       96.7       100
                                       Cefepime                                                              10.0   36.7   50.0       76.7       86.7       **100**                                                                                            
  *A. baumannii* (198)                 Cefoselis                                                      1.5    2.5    3.5    5.1        6.6        8.6        16.2       18.7       18.7       18.7       19.2       21.2       26.3       40.4       71.2       **100**
                                       Cefepime                                                       1.0    2.0    3.5    4.5        5.6        6.6        12.1       16.2       18.7       19.7       24.2       36.9       52.0       84.3       **93.9**   100
  *P. aeruginosa* (30)                 Cefoselis                                                                                                 3.3        36.7       50.0       63.3       73.3       73.3       73.3       76.7       **96.7**   96.7       100
                                       Cefepime                                                                                                  3.3        53.3       56.7       70.0       73.3       80.0       80.0       **96.7**   100                   
  MRSA (97)                            Cefoselis                                                                                                            2.1        3.1        18.6       27.8       32.0       **96.9**   100                              
                                       Cefepime                                                                                                                        1.0        2.1        5.2        13.4       18.6       25.8       28.9       28.9       **100**
  MSSA (100)                           Cefoselis                                                      3.0    3.0    3.0    3.0        3.0        4.0        64.0       82.0       87.0       **90.0**   92.0       100                                         
                                       Cefepime                                                       3.0    3.0    3.0    3.0        3.0        3.0        5.0        57.0       78.0       83.0       87.0       88.0       89.0       **90.0**   93.0       100
  PSSP (25)                            Cefoselis                                                      32.0   72.0   80.0   84.0       **92.0**   92.0       96.0       96.0       96.0       96.0       96.0       100                                         
                                       Cefepime                                                       4.0    72.0   76.0   80.0       88.0       **92.0**   96.0       96.0       96.0       96.0       96.0       100                                         
  PRSP (15)                            Cefoselis                                                                                                 6.7        40.0       40.0       86.7       **100**                                                           
                                       Cefepime                                                                                                             20.0       60.0       **100**                                                                      
  Beta-hemolytic *streptococci* (27)   Cefoselis                                                      40.7   85.2   88.9   **92.6**   92.6       92.6       92.6       92.6       92.6       92.6       92.6       92.6       92.6       92.6       92.6       100
                                       Cefepime                                                       37.0   40.7   85.2   **92.6**   92.6       92.6       92.6       92.6       92.6       92.6       92.6       92.6       92.6       92.6       92.6       100
  Viridans group *streptococci* (15)   Cefoselis                                                      26.7   46.7   93.3   **100**                                                                                                                             
                                       Cefepime                                                       26.7   33.3   40.0   53.3       **93.3**   93.3       93.3       93.3       93.3       100                                                               

ESBL, extended-spectrum β-lactamase; MRSA, methicillin-resistant

S. aureus

; MSSA, methicillin-sensitive

S. aureus

; PSSP, penicillin-susceptible

S. pneumoniae

; PRSP, penicillin-resistant

S. pneumoniae

; MIC, minimum inhibitory concentration.

a

MIC90 values are in boldface.

Discussion {#S4}
==========

The Enterobacteriaceae family is a major group of pathogens causing several community- and hospital-acquired infections, among which the ESBL rates in *E. coli* and *K. pneumoniae* in China have been reported as high as 60--70% and 30--40%, respectively ([@B15], [@B17]). According to our previous study, the genotype distribution of ESBL-producing strains among bacterial species was diverse, and *blaCTX-M* was the major ESBL gene, with occurrences in 99.5% of *E. coli*, 91.1% of *K. pneumoniae*, and 97.5% of *P. mirabilis* strains ([@B16]). In the present study, cefoselis and cefepime both showed poor activities against ESBL-producing *E. coli*, *K. pneumoniae*, and *P. mirabilis*, which may be attributed to the specific ESBL genes present in China, albeit further studies are needed for confirmation.

Against other Enterobacteriaceae strains, cefoselis exhibited a slightly lower antimicrobial activity than cefepime, but a higher activity than third-generation cephalosporins. The relatively high activities of fourth-generation cephalosporins against Enterobacteriaceae may be attributed to the low affinity for chromosome-mediated AmpC β-lactamases ([@B2]), which are the common β-lactamases in Enterobacteriaceae isolates from China. A multicenter, double-blind, randomized clinical trial in China revealed equal clinical efficacy and safety of intravenous cefoselis and cefepime injection for the treatment of acute, moderate, and severe bacterial infections ([@B8]).

*Acinetobacter baumannii* was one of the bacteria considered to be of maximum resistance and is classified as a priority category according to the bacterial groups classified by priority categories of need for new antibiotics ([@B14]). In this study, *A. baumannii* exhibited low susceptibility to most of the tested antibiotics, with susceptibility rates ranging from 5.1 to 58.6%. Against *P. aeruginosa*, cefoselis and cefepime showed equal antimicrobial activities for this organism, with susceptibility rates of 73.3% each, which are slightly higher than those in a previous study in China; thus, these two antibiotics could be used to treat infections caused by *P. aeruginosa*, in combination with other antibiotics ([@B19]).

Although the prevalence of MRSA in China showed a markedly decreasing trend from 69.0% in 2005 to 35.3% in 2017, as per the China Antimicrobial Surveillance Network (CHINET) program, MRSA remains a major pathogen responsible for nosocomial infections ([@B5]). No isolates were found to be resistant to vancomycin, linezolid, and teicoplanin in this study. Tigecycline and TMP-SMX also showed good activities, which were similar to previous studies ([@B20]; [@B18]). Vancomycin, linezolid, and TMP-SMX were recommended by the Infectious Diseases Society of America (IDSA) to treat MRSA infections ([@B7]).

Teicoplanin can be an effective alternative to vancomycin for treating patients infected by MRSA as the two therapies are similar in both efficacy and safety ([@B10]). Tigecycline was often recommended as a second- or third-line agent for MRSA infections when alternative agents cannot be used ([@B11]). Ceftaroline fosamil was the first FDA-approved cephalosporin with any activity against MRSA, but the low susceptibility among MRSA isolates in China needs attention ([@B9]; [@B18]).

The bacterial isolates were collected from 2014 to 2016, and the susceptibility has certainly changed in the last 5 years for most organisms. More recently collected strains should be involved in further studies. This is a limitation of the study. In conclusion, cefoselis exhibited good antimicrobial activity against non-ESBL\[Frame1\]-producing *E. coli*, *K. pneumoniae*, *P. mirabilis*, and MSSA and was also potent against other Enterobacteriaceae, *P. aeruginosa*, and *Streptococcus*.
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